Publication | Closed Access

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Rheumatoid DisorderRheumatologyIntegrated Safety AnalysisMedicinePatient SafetyPharmacologyOsteoarthritisTherapeutic ControversyInflammatory Rheumatic DiseasePharmacotherapyPsoriatic ArthritisSafety ProfileRheumatoid Arthritis